TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3545273

Group type: EXPERIMENTAL
Intervention: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + vehicle control (+)‐glucose infusion (60 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: salbutamol (120 ng kg‐1 min‐1 for 30 min) + vehicle control (+)‐glucose infusion (90 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + salbutamol (120 ng kg‐1 min‐1 for 30 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: vehicle control (+)‐glucose infusion
Number of subjects: 8
Study: 30662456

Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: HD-tDCS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study: 27657514

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24183837

Group type: EXPERIMENTAL
Intervention: eGFR 20-44 mL/min/1.73m(2)
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: eGFR > 60 mL/min/1.73m(2)
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73m(2)
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1043
Study: 22526314

Group type: EXPERIMENTAL
Intervention: Polymorph form I of ST-246, 400 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymorph form V of ST-246, 400 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymorph form I of ST-246
Number of subjects: 0
Study: 20525992

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus gp100
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab alone
Number of subjects: 676

Group type: COMPARATOR
Intervention: gp100 alone
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus gp100 vs Ipilimumab alone
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Study drugs
Number of subjects: 676
Study: 17928878

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (300 mg/25 mg)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Irbesartan monotherapy (300 mg)
Number of subjects: 538

Group type: COMPARATOR
Intervention: HCTZ monotherapy (25 mg)
Number of subjects: 538
Study: 17366796

Group type: EXPERIMENTAL
Intervention: NP plus endostatin
Number of subjects: 67

Group type: COMPARATOR
Intervention: NP alone
Number of subjects: 67
Study: 12514682

Group type: EXPERIMENTAL
Intervention: 2-stage emergency department intervention (identification of high-risk patients and brief standardized nursing assessment)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2-stage emergency department intervention
Number of subjects: 4

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 4
Study: 11707864

Group type: EXPERIMENTAL
Intervention: Bexarotene gel applied to target lesions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose oral bexarotene (300 mg/m²)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-dose oral bexarotene (6.5 mg/m²)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose oral bexarotene (300 mg/m²) for erythrodermic CTCL
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atorvastatin (60 mg/day)
Number of subjects: 8
Study: 8806288

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Recombinant hepatitis B vaccine (comparator)
Number of subjects: 1221
Study: 1321006

Group type: EXPERIMENTAL
Intervention: Six-drug alternating combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-drug 'standard' combination treatment
Number of subjects: 0
Study: 6148522

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30902791

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D fortified snack bars (2000 mg Ca and 1000 IU vitamin D per day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (Ca + D)
Number of subjects: 197
Study: 29803270

Group type: EXPERIMENTAL
Intervention: ASA24 (Automated Self-Administered 24-Hour Dietary Assessment Tool)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: AMPM (Interview-Administered Automated Multiple Pass Method)
Number of subjects: 1081
Study: 25496523

Group type: EXPERIMENTAL
Intervention: Family School Success (FSS) program
Number of subjects: 139

Group type: COMPARATOR
Intervention: CARE (active-control condition)
Number of subjects: 139
Study: 24461162

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 29
Study: 21902692

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel
Number of subjects: 200

Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 200
Study: 19190228

Group type: EXPERIMENTAL
Intervention: Biosand filter (BSF) households
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control households
Number of subjects: 154
Study: 17939615

Group type: EXPERIMENTAL
Intervention: External focus of attention during postural control training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Internal focus of attention during postural control training
Number of subjects: 36
Study: 12594145

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study: 10992842

Group type: EXPERIMENTAL
Intervention: Desflurane (2‐4% end‐tidal)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.75‐1.5% end‐tidal)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.4‐0.8% end‐tidal)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol infusion (75‐150 micrograms kg‐1 min‐1)
Number of subjects: 80
Study: 8854471

Group type: EXPERIMENTAL
Intervention: Pulsed therapy with oral dexamethasone, 40 mg/day on 4 consecutive days each month for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Number of subjects: 12
Study: 1291184

Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse (0.63% diluted to 0.1%)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stannous fluoride mouthrinse
Number of subjects: 55
Study: 6515368

Group type: EXPERIMENTAL
Intervention: salbutamol 0.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: pirbuterol 0.4 mg
Number of subjects: 12
Study: 31590640

Group type: EXPERIMENTAL
Intervention: Risk stratification based on sFlt-1/PlGF measurement and fullPIERS score, with recommendations to defer delivery for low-risk patients (sFlt-1/PlGF ≤38 AND fullPIERS< 10% risk).
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Active program of knowledge transfer about WHO recommendations for preeclampsia, including antenatal corticosteroids, antihypertensive therapy, and magnesium sulphate for seizure prophylaxis.
Number of subjects: 750
Study: 28731266

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1,000 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25805457

Group type: EXPERIMENTAL
Intervention: Left-cathodal/right-anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left-anodal/right-cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 0
Study: 23921600

Group type: EXPERIMENTAL
Intervention: Close monitoring of cerebral rStO2 and a treatment guideline to correct deviations in rStO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical intervention algorithm based on cerebral perfusion-oxygenation changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment guideline
Number of subjects: 0
Study: 21320700

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 76
Study: 19817986

Group type: EXPERIMENTAL
Intervention: Rapid compression ultrasound (CUS) examination
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Complete compression ultrasound (CUS) examination
Number of subjects: 1002
Study: 16699457

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 328
Study: 15955540

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy elderly group
Number of subjects: 65
Study: 10397375

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (400 mg loading dose followed by 200 mg once daily for up to 10 days)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Comparator drugs
Number of subjects: 1100
Study: 8673784

Group type: EXPERIMENTAL
Intervention: Cartoon illustrations
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard instructions without cartoons
Number of subjects: 234
Study: 1512761

Group type: EXPERIMENTAL
Intervention: loxoprofen Na (prodrug)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: proglumetacin maleate (prodrug)
Number of subjects: 29

Group type: COMPARATOR
Intervention: diclofenac Na (control)
Number of subjects: 29
Study: 6419519

Group type: EXPERIMENTAL
Intervention: Piribedil 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piribedil 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piribedil 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piribedil (all doses)
Number of subjects: 12
Study: 31093929

Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 0 min before meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 30 min before meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral insulin 338 administered 60 min before meal
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral insulin 338 administered 360 min before meal
Number of subjects: 44
Study: 29772035

Group type: EXPERIMENTAL
Intervention: MDI implants (3M ESPE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SlimLine implants (Dentium)
Number of subjects: 45
Study: 26468628

Group type: EXPERIMENTAL
Intervention: CPAP (10 to 12 cmH2O) during inpatient cardiac rehabilitation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard CR without CPAP
Number of subjects: 54
Study: 24844229

Group type: EXPERIMENTAL
Intervention: Reported BMI corrected using gender and body shape perception
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Reported BMI
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Regression of reported BMI by gender and socioeconomic status
Number of subjects: 341
Study: 22304443

Group type: EXPERIMENTAL
Intervention: Dynamic spectral imaging (DSI) colposcopy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Colposcopist impression
Number of subjects: 177
Study: 20379055

Group type: EXPERIMENTAL
Intervention: Coagulation factor IX
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Coagulation factor XI
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Alpha-2 antiplasmin
Number of subjects: 368

Group type: COMPARATOR
Intervention: Classical risk factors adjustment
Number of subjects: 368

Group type: COMPARATOR
Intervention: Factors II, V, X, XII, and plasminogen
Number of subjects: 368
Study: 19281913

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study: 16252734

Group type: EXPERIMENTAL
Intervention: Xinmaitong
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 200
Study: 14581665

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid stenosis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Symptomatic carotid stenosis
Number of subjects: 45
Study: 10320236

Group type: EXPERIMENTAL
Intervention: Aortic homograft preserved in antibiotic solution at 4 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Toronto stentless porcine valve
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle stentless valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medtronic Intact aortic valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stented valve
Number of subjects: 40
Study: 8708151

Group type: EXPERIMENTAL
Intervention: Intralesional IFN alfa-2a
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intralesional IFN alfa-2b
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of intralesional IFN alfa-2a and 2b
Number of subjects: 45
Study: 1876419

Group type: EXPERIMENTAL
Intervention: Hypnosis (HA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acupuncture (AA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study: 31410649

Group type: EXPERIMENTAL
Intervention: Kinesiotaping plus exercise program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 42
Study: 27862173

Group type: EXPERIMENTAL
Intervention: Nurse Navigator Programme
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 120
Study: 25239059

Group type: EXPERIMENTAL
Intervention: Cefozopran
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 376

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Carbapenem (Imipenem-cilastatin and Meropenem combined)
Number of subjects: 376
Study: 23642508

Group type: EXPERIMENTAL
Intervention: EuroSCORE II (ESII)
Number of subjects: 537

Group type: COMPARATOR
Intervention: additive EuroSCORE (addES)
Number of subjects: 537

Group type: COMPARATOR
Intervention: logistic EuroSCORE (logES)
Number of subjects: 537
Study: 21562091

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (DM-I)
Number of subjects: 2263
Study: 19161542

Group type: EXPERIMENTAL
Intervention: 2000 IU daily of vitamin D(2) for mothers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 60,000 IU monthly of vitamin D(2) for mothers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 400 IU daily of vitamin D(2) for infants
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Milk antirachitic activity
Number of subjects: 90
Study: 17450047

Group type: EXPERIMENTAL
Intervention: Fast/once daily titration (1.2 mg/kg/day over 3 days)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Slow/twice daily titration (1.2 mg/kg/day over at least 2 weeks)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Slow/twice daily titration
Number of subjects: 447
Study: 15016780

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with 400 mcg buserelin acetate daily followed by 6 mg of oral estradiol valerate starting on menstrual day 1
Number of subjects: 234

Group type: COMPARATOR
Intervention: No GnRH agonist therapy, starting 6 mg of oral estradiol valerate on day 1 of bleeding
Number of subjects: 234
Study: 11206232

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg twice daily
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg twice daily
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Formoterol (both doses)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Albuterol 180 microg four times daily
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541